News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NovaBay Pharmaceuticals, Inc. (NBY) CEO Comments On President Obama's 'Superbug' Budget Initiative And Reports By The Centers for Disease Control and Prevention (CDC) On Antibiotic Resistance


3/7/2014 8:56:52 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EMERYVILLE, Calif., March 6, 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic anti-microbial products, today commented on President Obama's antibiotic resistance budget initiative, which includes $30 million annually for the next five years to detect and prevent "superbug" infections. Superbugs are of great concern because they are resistant to even the strongest antibiotics. Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay commented on the worrisome new cases of antibiotic-resistant bacteria and on a plan that NovaBay scientists have developed to successfully fight the superbug threat.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES